The 'HAP' system predicts outcomes of liver cancer for patients undergoing TAE or TACE treatments. The score is based on four factors: 1) tumour size, and 2)-4) leves of proteins in the blood called albumin, bilirubin and alpha-fetoprotein. Large tumour size, low albumin, high bilirubin and high alpha-fetoprotein are closely associated with high mortality risk.